(Givinostat), on mice with diastolic dysfunction.

By Harrison Smith

The RNA-seq analysis of an HDAC inhibitor, ITF2357

Outline

- Background
- Procedure details
- QC of samples
- Differentially expressed Genes/Gene set enrichment
- Conclusion

Background

- Diastolic dysfunction (DD) Abnormal left ventricle functionality
- Studies indicate DD is attributed to cardiac myofibril relaxation.
- HDAC inhibitor, ITF2357, restores Diastolic functionality.
- RNA-seq analysis provides an observation of genetic expression

Aim

- Observe the effects of HDAC inhibition.
 - Determine differentially expressed genes in mice
 - Look at enrichment of curated gene sets
 - Infer positive and negative correlations with phenotype data with gene sets

Procedure

<u>Summary</u>

- Total RNA was isolated and sequenced from the whole hearts of mice.
- 20 biological replicates across two time points,
 - 4 weeks and 8 weeks, post uninephrectomy(UNX) surgery.

Negative Control : UNX + veh

Positive Control : UNX/DOCA + veh

Experimental group : UNX/DOCA + treatment

Procedure

Prep Protocol

- Whole heart cell tissues were lysed in the Zymo TRI Reagent
- The mRNA was poly-A selected
- Paired end reads

RNA extraction/purification : Zymo R2050 Direct-zol RNA Miniprep Kit

RNA library prep : Ultra-directional RNA library prep NEBNext Kit

NGS Sequencing : Illumina NovaSeq 6000

Procedure

Downstream NGS analysis

Alignment + quantification

Fastqs aligned to mm10 (mouse) reference genome from UCSC using HISAT2

Replicates were quantified and normalized to determine the overall gene expression

Cufflinks → Cuffquant → Cuffnorm tool set

Dr. Lin's R script was used for pairwise correlations, normalized expression matrix, and GSEA ready inputs.

Visual of normalized gene expression levels across each biological group.

Used for quickly examining outliers or contaminations that might skew further analysis

Figures:

- 1. Box-plot represents unnormalized expression
- 2. Replicate scatter plots of normalized expression

The log2 expression here represents the unnormalized expression levels of total genes among replicates.

The first figure to assess before viewing pairwise correlations.

DOCA_5 : +Control mice 4 weeks


DOCA_9 : +Control mice 8 weeks

Sham_5 : -Control mice 4

S_9 : -Control 8 weeks

ITF_9 : exp + inhibitor 8 weeks

Unnormalized expression




Replicate scatter plot

normalized gene expression levels which are filtered by genes.

All pairwise comparisons of replicates are plotted by group.

Helpful in quickly identifying poor quality samples. The title of each figure provides the average of all comparisons in a replicate group.


Here we have high similarity among **Sham 4 weeks** replicates at avg 0.9928



0 2 4 6 8 10

Sham 8 0.9895 Replicates for S_91 Avg. pairwise correlation of 0.9895 *** 0.9854 0.9886 0.9869 5 91 2 *** 0.9884 0.9926 5_91_0 *** 0.9914 S_91_3 S_91_1

0 2 4 6 8 10




DOCA 4 weeks

A replicate group boxed in red appears to cause a noticeable deviation compared to the other groups.

This replicate was dropped prior to downstream analysis.

Replicates for DOCA 56 Avg. pairwise correlation of 0.9742




DOCA at 8 weeks

Replicate # 2 shows an even weaker correlation.

Will also be dropped.

Replicates for DOCA_9 Avg. pairwise correlation of 0.9676




Gene set enrichment

Gene set enrichment analysis was performed with GSEA

"gene sets, which represent group of genes that are grouped together based on their common biological function and/or involvement in the same biological pathways"

Curated sets come from the Molecular Signatures Database (MSigDB) on the Broad Institute web page



The peak of the graph represent the Enrichment Score

From left to right is a list of ranked genes from most upregulated to most downregulated

Positive score shows correlation with up regulated genes in the subset. (leading edge subset)

Negative score indicates downregulation correlation

Example:




Fig 1: Enrichment plot: P53_DOWN_KANNAN
Profile of the Running ES Score & Positions of GeneSet Members on the Rank Ordered List

The entire GSEA output documentation for each enriched pathway is provided in the project folder.

GSEA provides top 20 enrichment plots for upregulation of phenotype 1 and 20 plots for downregulation of phenotype 2 in comparison but there are typically more.

Meaning, enrichment plots for Phenotype 1 show upregulation enrichment in a pathway (gene set) compared to the phenotype 2 genes.

Enrichment plots for phenotype 2 in the same output show correlation with down regulated genes in that pathway.

Viewing individual enrichment plots and scrolling down will provide the leading edge subset genes (significant enrichment of DE genes) that make up the enriched pathway.

GSEA (example)

Here we see enrichment for downregulated genes of this pathway for Sham 8




Fig 1: Enrichment plot: AMIT_EGF_RESPONSE_40_HELA
Profile of the Running ES Score & Positions of GeneSet Members on the Rank Ordered List

This plot shows enrichment for upregulated genes in this pathway




Fig 1: Enrichment plot: LIAN_LIPA_TARGETS_6M

Profile of the Running ES Score & Positions of GeneSet Members on the Rank Ordered List

D8 vs S8

- Top 5 enriched pathways for up-regulation of genes in DOCA 8
- The rest can easily be viewed in the gsea project fold.
- Just open the index html and click on snapshot of results

- 1.Lian-LIPA_targets
- 2. Verhaak glioblastoma mesenchymal
- 3. Invasive Breast cancer
- 4. Mclachlan dental caries
- 5. Kim GLI52_targets_up

D8 vs S8

- Top 5 enriched pathways for down-regulation of genes in Sham 8 group
- This is relative to DOCA 8 group

- 1.AMIT EGF response HELA
- 2. Jechlinger Epithelial mesenchymal transition
- 3. AMIT serum response
- 4. AMIT EGF response MCF10A
- 5. RASHI response to IONIZING radiation

- Top 5 enriched pathways for up-regulation of genes in DOCA8 group
- Compared to ITF

- 1. Altemeier response to lps with mechanical ventilation
- 2. Poola invasive breast cancer
- 3. Mclachlan dental caries up
- 4. Croonquist IL6 deprivation dn
- 5. Croonquist NRAS signaling

D8 vs I8

- Top 5 enriched pathways for down-regulation of genes in ITF 8 group
- This is relative to DOCA 8 group

- **1.REACTOME** peptide chain elongation
- 2. KEGG ribosome
- 3. AMIT serum response
- 4. AMIT EGF response MCF10A
- 5. RASHI response to IONIZING radiation

18 vs S8

- Top 5 enriched pathways for up-regulation of genes in ITF 8 group
- This is relative to Sham 8 group

- 1. Sotiriou breast cancer grade 1 vs 3 up
- 2. Whiteford pediatric cancer markers
- 3. Rosty cervical cancer proliferation cluster
- 4. Lee early T lymphocyte up
- 5.Mori Large Pre Bll lymphocyte up

18 vs S8

- Top 5 enriched pathways for down-regulation of genes in Sham 8 group
- This is relative to ITF 8 group

- **1.REACTOME** peptide chain elongation
- 2. KEGG ribosome
- 3. AMIT serum response
- 4. AMIT EGF response MCF10A
- 5. RASHI response to IONIZING radiation

Enrichment in phenotype: DOCA_8 (1 samples)

- 2389 / 3310 gene sets are upregulated in phenotype DOCA_8
- 588 gene sets are significant at FDR < 25%
- 271 gene sets are significantly enriched at nominal pvalue < 1%
- 565 gene sets are significantly enriched at nominal pvalue < 5%
- Snapshot of enrichment results
- · Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- · Guide to interpret results

Enrichment in phenotype: Sham_8 (1 samples)

- 921 / 3310 gene sets are upregulated in phenotype Sham_8
- 50 gene sets are significantly enriched at FDR < 25%
- 44 gene sets are significantly enriched at nominal pvalue < 1%
- 131 gene sets are significantly enriched at nominal pvalue < 5%
- · Snapshot of enrichment results
- · Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- Guide to interpret results



SampleName
H2-06
GM1987
001367
RPL34-PS1
MT2
NMRK2 SERPINA3G ANGPTL4
SERPINA3G
ANGPTL4
GM694
PRG4
NR4A3
IL33
H2-08
IL1R2
SELP
SYT12 CLCA3A1
CL CA3A1
U2.07
H2-07 CD300LF
CD300LF
PACSIN1
TTYH1
CLEC4E
TNFRSF11B TMEM252
TMEM252
MTHFD1L
CCL8
CCL8 ACTG2
ACTOZ
AUP8
LRP8
LCN2
URAH MCOLN2 CRLF1
MCOL N2
CRI E1
AI593442
A1393442
RUNX3
FCGR4
H2-05 SERPINA3N
SERPINASN
TIMPl
TNC
PPARGC1A
HC4ACD
MS4A6D
CNN1
CSF2RB2
HUC
ADAMTS4
CYSLTR1
SPHKI OO
TMEM100
PTX3
MMP8

	HBB-BS
	AMD1
	ASS1
	DYNLT1F
38	OTUD1
	EGR1
	FOS
Н	FUS
	IRS2
	GM28979
Ш	BTG2
	OVGP1
	RTN4R
	NR4A1
	F0SB
	PLEKHH1
	GM7334
	IER2
	IER5
38	EGR3
	JUN
	KLF2
	CCL24
	GM6377
	PBLD1
	CHP2
	PLA2G4E
	DUSP1
	EGR2
	NTF3
	PFKFB1
	TMPRSS4
	TOX
	FAM212B
	KLK14
	AOP4
38	TBX6
	PPP1R3B
	FRMD5
	JUNB
	LPAR3
	7ED26
	ZFP36
	PCDH12
	EDN1
	SNCA
	BTBD11
	NR4A2
	FAM150B
	PKD2L2
	LECT1

Enrichment in phenotype: DOCA_8 (1 samples)

- 2256 / 3310 gene sets are upregulated in phenotype DOCA 8
- 1007 gene sets are significant at FDR < 25%
- 439 gene sets are significantly enriched at nominal pvalue < 1%
- 768 gene sets are significantly enriched at nominal pvalue < 5%
- · Snapshot of enrichment results
- · Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- · Guide to interpret results

Enrichment in phenotype: ITF_8 (1 samples)

- 1054 / 3310 gene sets are upregulated in phenotype ITF_8
- 144 gene sets are significantly enriched at FDR < 25%
- 82 gene sets are significantly enriched at nominal pvalue < 1%
- 187 gene sets are significantly enriched at nominal pvalue < 5%
- · Snapshot of enrichment results
- · Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- Guide to interpret results

(N)
1
C7 N
SampleName
H2-06
GM1987
INSL3
SAP25
TOP2A PTX3
MMP8
S100A8
ILIB
NGP CCNB2
ADAMTS4
PRC1
IL1R2
CCNA2 CLEC4E
CD300LF
TNC
MKI67
S100A9
CXCL1 CCL2
THBS1
ARNTL
PILRA
CXCR2 CDK1
SELE
CD79A
ATP6V0C-PS2
KIF22 CD79B
0LFR1396
MCOLN2
ZCCHC5
SLFN1 TNFAIP6
LCN2
MMP9
EAR2
MS4A4B
ADIG ATF3
KLK1B26
LYZ1
ACTA1
SELP PRND
CCL5
GIMAP3

	ASS1	10
-	AMD1	-
4		
	RPS27	- 8
	LPAR3	
	0LFR872	10
Ħ	FBX044	
4		
	PSCA	- 6
	KLK14	
	RNF208	- 13
-	TMEM35	7.0
4		- 10
_	PPP1R1B	- 0
	C030013G03RIK	
	P0U3F1	8
	SEC14L2	- 70
+		100
_	GM7334 RAMP1	- 0
	RAMP1	
	ANGPTI 7	
	SOCS1	
+		- 0
4	EGR1	- 8
	INMT	
	ZFP286	
	GDAP10	7.0
7	FLYWCH2	100
+		
_	PBLD1	
	GM11837	- 8
	BC064078	
7	FADS6	16
н		-
4	MDK	_
	NDRG4	- 6
	FOS	
	GM4956	- 10
Ħ	6430710C18RIK	-
4		- 10
	GM28979	- 8
	CTH	
	SLC44A5	8
	0LFR39	- 70
	GDF10	100
		- 8
	GABRA3	
	CHP2	- 8
	HMGA1-RS1	27.5
	WISP2	15
		- 2
	KCNV2	
	LPPR2	- 8
	PACRG	
	TRNP1	13
		- 2
	APOL10B	1.00
	MCTP1	- 8
	IER2	
	CCL21A	10
f	OSGIN1	
	OSOTIAT	

Enrichment in phenotype: ITF_8 (1 samples)

- 1658 / 3310 gene sets are upregulated in phenotype ITF 8
- 164 gene sets are significant at FDR < 25%
- 125 gene sets are significantly enriched at nominal pvalue < 1%
- 264 gene sets are significantly enriched at nominal pvalue < 5%
- Snapshot of enrichment results
- Detailed <u>enrichment results in html</u> format
- Detailed enrichment results in excel format (tab delimited text)
- · Guide to interpret results

Enrichment in phenotype: Sham 8 (1 samples)

- 1652 / 3310 gene sets are upregulated in phenotype Sham 8
- 475 gene sets are significantly enriched at FDR < 25%
- 219 gene sets are significantly enriched at nominal pvalue < 1%
- 428 gene sets are significantly enriched at nominal pvalue < 5%
- · Snapshot of enrichment results
- · Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- · Guide to interpret results



RPL34-PS1 RPS27 H2-08 H2-07 P0U3F1 PSCA NPPA ANGPTL4 HMGA1-RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRGA SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBP1B PCDH20 TITR WISP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A SERPINA3N AHSG ACOT1 HCARL SYPL2 SYN2 SYPL2 SYN2 PPPIR3G	SampleName
RPS27 H2-08 H2-07 P0U3F1 PSCA NPPA ANOPTL4 HMGA1-RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBR044 OLFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WTSP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINASI LBP FKBP1B PCDH20 TTR WTSP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINASN AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYP12 HAS1 D630024D03RIK SYP12	RPI 34-PS1
H2-08 H2-07 P0U3F1 PSCA NPPA ANGPTL4 HMGA1-RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBPIB FCH20 TITR WISP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	RPS27
H2-07 P0U3F1 PSCA NPPA ANGPTL4 HMGA1-RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TMEM35 LBP FKBPIB FKB	
POUJÉTI PSCA NPPA ANGPTL4 HMGA1-RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL 33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 0LFR872 DKK3 TMEM35 LBP FKBPIB	
PSCA NPPA ANGPTL4 HMGA1 - RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TMEM35 LBP FKBPIB	
NPPA ANOFTL4 ANOFTL4 HMGAI - RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 0LFR872 DKK3 TMEM35 LBP FKBP1B PKDP120 TTR WISP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINASI ACT1 HCARL SYT12 HAS1 D630024D03RIK SYP12 LBS1 D630024D03RIK SYP12 HAS1 D630024D03RIK	
ANGFTL 4 HMGA1-RS1 ASS1 H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 0LFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYP12 HAS1 D630024D03RIK SYP12	
HMGAL - RS1 ASS1 HS2-Q5 MT2 TPSB2 LRRC52 GMG94 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-Q9 FBX044 OLFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNN1 CCLB ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
ASSI H2-05 H72 TPSB2 LRRC52 GM694 MDK II.33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 0LFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TIR WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3G	HMGA1 - RS1
H2-05 MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBPIB PCDH20 TITR WISP2 CYSLTRI FETUB CNN1 CCLB ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2	
MT2 TPSB2 LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PR64 SERPINA3G H2-09 FBX044 OLFRB72 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2	H2-05
TPSB2 LRRC52 GM694 MDK IL 33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 01.FB872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNNI CCLB ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
LRRC52 GM694 MDK IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBPIB PCDH20 TITR WISP2 CYSLTRI FETUB CNN1 CCLB ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2	
GM694 MDK II.33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CCLB ACTG2 PPARGC1A FBP1 NDRG4 SERPINASN AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYP12	LRRC52
MDK IL 33 LRRC10B SEC1 4L2 CL CA3A1 PRG4 SERPINA3G H2-09 EBX044 OLFR872 DKX3 TMEM35 LBP FKBP1B PCDH20 TITR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SY12 HAS1 D630024D03RIK SYPL2 SYN2	
IL33 LRRC10B SEC14L2 CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBPIB PCDH20 TITR WISP2 CYSLTRI FETUB CNNI CCLB ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2	
RRC10B SEC14L2 CLC43A1 PRG4 SEPINA3G H2-09 FBX044 01-FB872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
SEC1.4L.2 CL.CA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DIKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	L RRC10B
CLCA3A1 PRG4 SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBP1B PCDH20 TITR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	SECTAL 2
PRG4 SERPINA3G H2-09 FBX044 01-FB872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGCIA FBP1 NDRG4 SERPINASN AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	CI CV3VI
SERPINA3G H2-09 FBX044 OLFR872 DKK3 TIMEM35 LBP FKBP1B PCDH20 TITR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
H2-09 FBX044 OLFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINASN AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2	
FBX044 OLFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
OLFR872 DKK3 TMEM35 LBP FKBP1B PCDH20 TITR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	112 40
DKK3 TMEM35 LBP FKBP1B FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINASN AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	01 ED072
TMEM35 LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
LBP FKBP1B PCDH20 TTR WISP2 CYSLTR1 FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
FKBP1B PCDH20 TTR WISP2 CYSLTRI FETUB CNN1 CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
PCDH20 TITR WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGCIA FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARI SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
TTR WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGCIA FBP1 NDRG4 SERPINASN AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
WISP2 CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGCIA FBPI NDRG4 SERPINA3N AHSG ACOTI HCARI SYT12 HASI D630024D03RIK SYPL2 SYN2	
CYSLTRI FETUB CNNI CCL8 ACTG2 PPARGCIA FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARI SYT12 HASI D630024D03RIK SYPL2 SYN2	WTCD2
FETUB C(NNI) CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	CVSI TRI
CNNI CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	CETIE
CCL8 ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
ACTG2 PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
PPARGC1A FBP1 NDRG4 SERPINA3N AHSG ACOT1 HCAR1 SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
FBP1 NDRG4 SERPINA3N AHSG ACOTI HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
NDRG4 SERPINA3N AHSG ACOT1 HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2 SYN2	
SERPINA3N AHSG ACOTI HCARI SYT12 HASI D630024D03RIK SYPL2 SYN2	
AHSG ACOTI HCARL SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
ACOTI HCARI SYTI2 HASI D630024D03RIK SYPL2 SYN2	
HCAR1 SYT1.2 HAS1 D630024D03RIK SYPL2 SYN2	
SYT12 HAS1 D630024D03RIK SYPL2 SYN2	
D630024D03RIK SYPL2 SYN2	SVT12
D630024D03RIK SYPL2 SYN2	HASI
SYPL2 SYN2	
SYN2	
PPP1R3G	SYN2
	PPP1R3G

4	HBB-BS
	SAP25
	DYNLT1F
	INSL3
	TOP2A
	LYZ1
	EAR2
	ATF3
	PRND
	CD79B
	NGP
	CCL2
	CD79A
	CXCL 1
	PRC1
	TRS2
1	CCNB2
٦	ARNTI
1	RTN4R
٦	CCI 24
7	THBS1
٦	MKT67
3	CCI 7
٦	TNE
4	OTUD1
1	SELE.
3	CCNA2
1	ERRFI1
4	0LFR1393
1	DETNI A
3	CNTN2
1	PLEKHH1
4	S100A8
١	DUSP8
1	CCDC60
١	KIESS
١	NR/A1
١	HIST1H2BL
١	GM11665
١	ZCCHC5
	MS4A4B
١	FOSB
١	
1	MMP12 TNFAIP3
١	TNFAIP3 ATP6V0C-PS2
١	AP00-PS
١	APUU-PS
1	FIAS
١	APLIN CMC207
	GM6307
í	KLK1B26

Conclusion

By viewing the index for each group you can determine the quantity of enriched gene sets.

Comparing the two reveals significant up and down regulation of genes for the specified pathway.

This helps narrow down enrichment for pathways that are present in the control groups